MX2016014760A - Niacinamida para inducir generacion de peptidos antimicrobianos. - Google Patents

Niacinamida para inducir generacion de peptidos antimicrobianos.

Info

Publication number
MX2016014760A
MX2016014760A MX2016014760A MX2016014760A MX2016014760A MX 2016014760 A MX2016014760 A MX 2016014760A MX 2016014760 A MX2016014760 A MX 2016014760A MX 2016014760 A MX2016014760 A MX 2016014760A MX 2016014760 A MX2016014760 A MX 2016014760A
Authority
MX
Mexico
Prior art keywords
niacinamide
antimicrobial peptides
inducing generation
skin
generation
Prior art date
Application number
MX2016014760A
Other languages
English (en)
Inventor
Majumdar Amitabha
Swamy Mathapathi Mruthyunjaya
Palanisamy Bharath
Sampath Kumar Ramya
Kumar Tiwari Jyoti
Original Assignee
Unilever Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever Nv filed Critical Unilever Nv
Publication of MX2016014760A publication Critical patent/MX2016014760A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Birds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invención se refiere al nuevo uso de niacinamida para disparar la generación de AMP (péptidos antimicrobianos) sobre la piel. Esto tiene aplicación para mejorar la inmunidad de la piel, cuero cabelludo y cavidad oral contra el ataque por microorganismos.
MX2016014760A 2014-05-12 2014-05-12 Niacinamida para inducir generacion de peptidos antimicrobianos. MX2016014760A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2014/059590 WO2015172801A1 (en) 2014-05-12 2014-05-12 Niacinamide for inducing generation of antimicrobial peptides

Publications (1)

Publication Number Publication Date
MX2016014760A true MX2016014760A (es) 2017-03-06

Family

ID=50771476

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016014760A MX2016014760A (es) 2014-05-12 2014-05-12 Niacinamida para inducir generacion de peptidos antimicrobianos.

Country Status (8)

Country Link
JP (1) JP6446065B2 (es)
CN (2) CN106413680A (es)
BR (1) BR112016024400A2 (es)
EA (1) EA031758B1 (es)
MX (1) MX2016014760A (es)
PH (1) PH12016502047A1 (es)
WO (1) WO2015172801A1 (es)
ZA (1) ZA201607105B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3851093B1 (en) 2015-08-10 2024-05-22 Mary Kay, Inc. Topical compositions
US10952952B2 (en) 2015-10-05 2021-03-23 Conopco, Inc. Skin lightening composition
CA3021920C (en) * 2016-05-10 2024-02-13 Unilever Plc A topical antimicrobial composition
US10869862B2 (en) 2016-05-26 2020-12-22 Conopco, Inc. Antimicrobial compositions for topical use
WO2018218012A1 (en) 2017-05-24 2018-11-29 Follea International Synephrine compositions
WO2019086327A1 (en) 2017-10-30 2019-05-09 Unilever N.V. Use of niacinamide for microbiome balancing
WO2019121529A1 (en) 2017-12-18 2019-06-27 Unilever N.V. A topical composition
MX2020006280A (es) 2017-12-18 2021-11-12 Unilever Ip Holdings B V Una composición tópica basada en un derivado de niacinamida.
US20200404915A1 (en) 2018-03-13 2020-12-31 Conopco, Inc., D/B/A Unilever A sanitizer composition
WO2024041910A1 (en) * 2022-08-25 2024-02-29 Unilever Ip Holdings B.V. Inactivation or kill of virus and compositions thereof
WO2024042554A1 (en) * 2022-08-25 2024-02-29 Istituto Fondazione Di Oncologia Molecolare Ets A pharmaceutical composition for treatment of viral infections

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN892496A0 (en) * 1996-03-25 1996-04-18 Technical Consultancy Services Pty Limited Acne treatment
US7026308B1 (en) * 1999-06-25 2006-04-11 The Procter & Gamble Company Topical anti-microbial compositions
BRPI0518160A (pt) * 2004-10-15 2008-11-04 Bayer Consumer Care Ag composições ácidas e compensadas paa cuidados com a pele compreendendo nicotinamida e um agente de absorção
CN101019865A (zh) * 2007-01-23 2007-08-22 中国医学科学院皮肤病医院 抗炎、保湿、祛斑的复方烟酰胺药用组合物
US20130052162A1 (en) * 2010-04-20 2013-02-28 Cedars-Sinai Medical Center Boosting immune defense by upregulating ccaat/enhancer binding protein epsilon
EP2624835A4 (en) * 2010-10-10 2014-07-30 Dermipsor Ltd COMPOSITIONS FOR TREATING SCORIASIS OF SCALP
FR2973699B1 (fr) * 2011-04-05 2013-04-26 Oreal Nouvel actif apte a induire au stimuler la production de peptides anti microbiens dans le cuir chevelu, utile pour prevenir et/ou traiter les etats pelliculaires du cuir chevelu
US8293790B2 (en) * 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
DE102012002592A1 (de) * 2012-02-13 2013-08-14 Dr. Kurt Wolff Gmbh & Co. Kg Verwendung eines Mittels zur Stimulation der Gen-Expression antimikrobieller Peptide (AMP)
US10426765B2 (en) * 2012-06-15 2019-10-01 Conaris Research Institute Ag Pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
EP3120850B1 (en) * 2012-12-14 2018-11-07 Unilever N.V. Niacinamide for inducing generation of antimicrobial peptides

Also Published As

Publication number Publication date
PH12016502047A1 (en) 2017-01-09
WO2015172801A1 (en) 2015-11-19
CN113908074A (zh) 2022-01-11
EA031758B1 (ru) 2019-02-28
EA201692284A1 (ru) 2017-03-31
BR112016024400A2 (pt) 2017-08-15
JP2017515829A (ja) 2017-06-15
ZA201607105B (en) 2018-05-30
CN106413680A (zh) 2017-02-15
JP6446065B2 (ja) 2018-12-26

Similar Documents

Publication Publication Date Title
PH12016502047A1 (en) Niacinamide for including generation of antimicrobial peptides
MX2023008686A (es) Polinucleotidos moduladores.
MX2017005834A (es) Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
MX2015009106A (es) Composiciones de solución sólida y su uso en el tratamiento del dolor intenso.
CA163246S (en) Handle for toothbrush
AU2015296298A8 (en) Flagellin-based agents and uses including effective vaccination
GB2541571A (en) Pharmaceutical compositions
MX2017005457A (es) Metodos y compuestos agonistas de gip.
SG10201910792WA (en) Vascularized tissue, skin or mucosa equivalent
EP3685819C0 (en) SOLID ANHYDROUS COSMETIC COMPOSITION, PREPARATION METHOD, COSMETIC TREATMENT PROCESSES AND ASSOCIATED KIT
PH12017500836A1 (en) Transdermal formulations
MY193650A (en) Extracellular matrix compositions
MX2017011223A (es) Variantes de protoxina ii y metodos de uso.
MX2021010886A (es) Uso de medicamentos para disminuir la evolucion de la enfermedad de parkinson.
MY190747A (en) Method for producing silazane-siloxane copolymers and the use of such copolymers
PH12016502530A1 (en) Pharmaceutical compositions comprising dgla and use of same
EP3104932A4 (en) Self-contained, handheld bipolar cortical stimulator
MX359181B (es) Hidrolizado de colágeno y uso del mismo.
SG10201900598TA (en) Factor viii formulation
MX2017010883A (es) Composicion para el tratamiento de la infertilidad.
EP3162358A4 (en) Skin whitening composition containing chemokine
PH12017501979A1 (en) Pharmaceutical compound
MX2017003949A (es) Derivados peptidicos novedosos y sus usos.
MX2016004961A (es) Procedimientos y composiciones para el tratamiento de infecciones por s. equi.
MX2018008138A (es) Composicion de colorante acuosa y sus usos.

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: UNILEVER IP HOLDINGS B.V.